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antinociceptive eﬀects of opioids remain uncertain. We
studied these interactions with the goal of highlighting the
involvement of the cannabinoid system in morphine-
induced analgesia. In both phases of the formalin test, intra
paw and intrathecal morphine produced similar antinocicep-
tive eﬀects in C57BL/6, cannabinoid type 1 and type 2 recep-
tor wild-type (respectively cnr1WT and cnr2WT) mice. In
cnr1 and cnr2 knockout (KO) mice, at the dose used the
antinociceptive eﬀect of intra paw morphine in the inﬂam-
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and 76%, respectively. Similarly, the antinociceptive eﬀect
of 0.1 lg spinal morphine in the inﬂammatory phase was
abolished in cnr1KO mice and decreased by 90% in cnr2KO
mice. Interestingly, the antinociceptive eﬀect of morphine in
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Open access under CC BYcnr1KO mice. Notably, systemic morphine administration
produced similar analgesia in all genotypes, in both the for-
malin and the hot water immersion tail-ﬂick tests. Because
the pattern of expression of the mu opioid receptor (MOP),
its binding properties and its G protein coupling remained
unchanged across genotypes, it is unlikely that the loss of
morphine analgesia in the cnr1KO and cnr2KO mice is the
consequence of MOP malfunction or downregulation due
to the absence of its heterodimerization with either the
CB1 or the CB2 receptors, at least at the level of the spinal
cord.
 2013 The Authors. Published by Elsevier Ltd.
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Among several pharmacological properties, analgesia is
the most common feature shared by the cannabinoid
and opioid systems (Manzanares et al., 1999; Massi
et al., 2001). The cannabinoid and opioid receptors
display similar properties. They both belong to the Gi/o
protein-coupled receptor family and are coupled to
similar intracellular signaling mechanisms (Bidaut-
Russell et al., 1990; Childers et al., 1992; Howlett,
1995). Indeed, the cannabinoids mediate their
pharmacological eﬀects through at least two types of
receptors, namely CB1 (Matsuda et al., 1990) and CB2
(Munro et al., 1993). The anatomical distribution of the
CB1 receptor is consequent with its functions, including
the modulation of pain perception at the central, spinal
and peripheral levels (Hohmann, 2002; Walczak et al.,
2005, 2006; Agarwal et al., 2007; Lever and Rice,
2007). By contrast, CB2 receptor expression seems to
be found predominantly in the peripheral tissues (Munro
et al., 1993; Galiegue et al., 1995; Schatz et al., 1997;
Jhaveri et al., 2007). However, the expression of this
receptor has also been described on brainstem neurons
(Van Sickle et al., 2005) and in microglial cell cultures
(Beltramo et al., 2006). Opioids mediate their
pharmacological eﬀects mainly through three types of
receptors: mu (MOP) (Yasuda et al., 1993), delta (DOP)
(Evans et al., 1992; Kieﬀer et al., 1992) and kappa
(KOP) (Chen et al., 1993). Although they are found
throughout the central nervous system (CNS) and in the
peripheral tissues, opioid receptors are primarily
expressed at high levels in several brain areas involved
in pain perception (Pol and Puig, 2004; Bodnar, 2012).-NC-ND license.
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modulation are reciprocal. Although the role of opioids in
cannabinoid antinociceptive eﬀects has been
documented (Maldonado and Valverde, 2003;
Cichewicz, 2004), there is little information regarding the
involvement of the cannabinoid system in the
antinociceptive mechanisms of opioids. Indeed, it was
recently demonstrated that the CB1 antagonist AM251
counteracts morphine-induced antinociception in an
inﬂammatory pain model (da Fonseca Pacheco et al.,
2008; Pacheco Dda et al., 2009) and in the tail-ﬂick test
in mice (Pacheco Dda et al., 2009). These observations
led to the hypothesis that MOP activation could induce
local release of endocannabinoids and that the
subsequent peripheral (da Fonseca Pacheco et al.,
2008) or central (Pacheco Dda et al., 2009) activation of
the cannabinoid receptors CB1 and/or CB2 could
contribute to the antinociceptive eﬀects of morphine. A
role for the endocannabinoid system in the inhibition of
MOP mRNA expression and signaling was also recently
described (Paldyova et al., 2008), demonstrating that
intraperitoneal administration of the CB2 antagonist
SR144528 attenuates MOP activity through CB2
cannabinoid receptors (Paldy et al., 2008; Paldyova
et al., 2008).
While experiments using pharmacological tools to
modify cannabinoid signaling suggested that
endocannabinoids are clearly involved in the
antinociceptive eﬀects of opioids, studies using
transgenic mice are not conclusive. Thus, the role and
the importance of the cannabinoid system in the
antinociceptive eﬀects of opioids remain uncertain. The
aim of this study was therefore to investigate whether
opioid and cannabinoid systems can interact at various
levels of the neuraxis. We evaluated the role of the
cannabinoid system in peripheral (i.e. local injection),
spinal and systemic antinociception induced by the
activation of MOP following morphine administration in
C57BL/6, cnr1WT, cnr1KO, cnr2WT and cnr2KO mice.EXPERIMENTAL PROCEDURES
Animals
Male C57BL/6, cnr1WT, cnr1KO, cnr2WT and cnr2KO
mice (25–30 g at the time of testing) were used in the
current study. They were housed in groups of two to
four in standard plastic cages with sawdust bedding in a
climate-controlled room. The mice were maintained
under a 14-h light/dark cycle (light period 06:00–
20:00 h). All experiments were conducted between
07:00 and 12:00 h. The mice were allowed free access
to food pellets and water. The C57BL/6 mice were
purchased from Charles River, St-Constant, Quebec,
Canada, whereas the cnr1 and cnr2 transgenic mice
were obtained from Pr. Beat Lutz (Institute of
Physiological Chemistry and Pathobiochemistry,
University of Mainz, Germany) and Jackson Laboratory
(Bar Harbor, ME, USA), respectively. These colonies
were maintained in-house. This research protocol was
approved by the Local Animal Care Committees at the
Universite´ de Montre´al and Universite´ de Sherbrookeand all procedures conformed to the directives of the
Canadian Council on Animal Care and guidelines of the
International Association for the Study of Pain. All
animal experiments were designed to minimize the
number of animals used and their suﬀering.
Drugs
Morphine sulfate (Morphine HP 50, lot #151034;
Sandoz, Boucherville, QC, Canada) was diluted in a
sterile saline solution (0.9% NaCl). Drugs were
administered into the dorsal surface of the left hind paw
(i.paw), intrathecally (i.t.) or subcutaneously (s.c.) before
intradermal (i.d.) formalin injection into the plantar
surface of the left hind paw. Morphine was administered
i.paw (1 lg/10 lL), i.t. (0.1 lg/5 lL), and s.c. (3 mg/kg
for the formalin test or 1, 3 and 10 mg/kg for the tail-ﬂick
test). Intrathecal injections were performed in non-
anesthetized mice as described previously (Fairbanks,
2003; Gendron et al., 2007). Brieﬂy, a 30-G ½ needle
mounted on a 10-lL Luer-tip Hamilton syringe (VWR)
was inserted into the L5–L6 intervertebral space, and
5 mL of morphine was injected. Saline was used as
vehicle control. The appropriate placement of the needle
was conﬁrmed by the observation of a light ﬂick of the tail.
Behavioral studiesFormalin test. The formalin test is a well-established
model of tonic pain that is characterized by a transient,
biphasic nociceptive response (Tjolsen et al., 1992).
The ﬁrst phase is characterized by the acute activation
of sensory receptors. The second phase involves an
inﬂammatory reaction in the peripheral tissue and the
development of CNS sensitization. The mice were
acclimatized to the testing environment (a clear
Plexiglas box 30  30  30 cm) for 15–20 min or until
the cessation of explorative behavior. Thereafter, drugs
were injected i.paw, i.t., or s.c. with saline or morphine 5
or 10 min before a 10-lL i.d. injection of a 2%
formaldehyde solution (i.e., 5.4% formalin, Fisher
Scientiﬁc, Montreal, QC, Canada) into the plantar
surface of the left hind paw. The experimenter was blind
to the drug treatments during testing. Following each
injection, the mice were immediately placed in the
observation chamber. Nociceptive behaviors were
observed for 60 min with the help of a mirror angled at
45 below the observation chamber to allow for an
unobstructed view of the hind paws.
The nocifensive behaviors were assessed using a
weighted score, as described previously (Dubuisson and
Dennis, 1977; Coderre et al., 1993). Following an
injection of formalin into the left hind paw, the
nociceptive mean score was determined for each 3-min
block during the 60-min recording period. In each 3-min
bin, the total time the animal spent in four diﬀerent
behavioral categories was recorded: (0), the injected
paw is comparable to the contralateral paw and is used
normally by the animal; (1), the injected paw has little or
no weight placed on it; (2), the injected paw is elevated
and is not in contact with any surface; and (3), the
J. Desroches et al. / Neuroscience 261 (2014) 23–42 25injected paw is licked, bitten or shaken. The weighted
nociceptive score ranged from 0 to 3 and was
calculated by multiplying the time (in seconds) spent in
each category by its assigned category weight,
summing these products and dividing by the total time
for each 3-min block of time. Nociceptive behavior was
thus rated using the following formula: Pain
score = (1T1 + 2T2 + 3T3)/180.
The area under the curve (A.U.C.) of ‘‘pain score-
time’’ above the weighted pain score of 1 was
calculated for the acute phase (0–9 min; Phase I) and
the inﬂammatory phase (21–60 min; Phase II) by the
trapezoidal rule using Prism 5.01.
Hot-water immersion tail-ﬂick test. To test the
antinociceptive eﬀects of s.c. morphine, tail-ﬂick
latencies were measured in C57BL/6, cnr1WT, cnr1KO,
cnr2WT and cnr2KO mice. The experimenter was blind
to the genotype during all testing. Brieﬂy, two
centimeters of the tail was immersed in a water bath
apparatus (IITC Life Science Inc., Woodland Hills, CA,
USA) maintained at 52 ± 0.5 C. Latency to response
was determined by a vigorous tail ﬂick. Baseline
measurements were obtained for each mouse before
s.c. morphine injection (zero time) and determined from
the average of three consecutive trials on the day of the
experiment. Subsequently, s.c. injection of morphine (1,
3 and 10 mg/kg) was carried out, and latencies to tail
withdrawal were measured every 10 min for a 60-min
period. A cut-oﬀ time of 10 s was imposed to minimize
tissue damage. If an animal reached the cut-oﬀ, the tail
was removed from the water, and the animal was
assigned the maximum score. The percentage of the
Maximal Possible Eﬀect (MPE) of s.c. morphine was
calculated according to the formula:
%MPE= 100  [(test latency)  (baseline latency)]/
[(cut-oﬀ time)  (baseline latency)].
Peripheral hind paw edema
At the end of the formalin test, maximal paw thickness
was measured at the base of the ipsilateral left hind
paw (i.e., formalin-injected hind paw) using a digital
micrometer (Mitutoyo Corporation, Aurora, IL, USA) with
a resolution of 1 lm (Petricevic et al., 1978; Guindon
et al., 2007). The level of inﬂammation induced by
formalin injection in all genotypes was also evaluated by
measuring the volume of the hind paw with a
plethysmometer (IITC Life Science Inc., Woodland Hills,
CA, USA). The hind paw was placed in a small water
bath and the volume displacement was measured. Two
measurements were carried out for both the ipsi- and
the contralateral hind paw, 60 min after formalin
injection. Data are expressed as the percentage (%) of
paw volume relative to the total body weight of the animal.
Saturation binding assays
Saturation binding assays using mouse spinal cord were
performed to determine the aﬃnity (Kd) and the number
(Bmax) of spinal MOP binding sites for each genotype
(n= 3 independent experiments per genotype). First,naive mice were brieﬂy anesthetized with isoﬂurane 5%
and euthanized. The spinal cord was then rapidly
dissected by laminectomy and pooled (n= 5 spinal
cords per assay) in tubes containing 15 mL of ice-cold
50 mM Tris buﬀer at pH 7.4 with protease inhibitors
(buﬀer A) until homogenization. Afterward, freshly
isolated mouse spinal cords were homogenized using a
Polytron PT-10-35 (Kinematica, Inc., Bohemia, NY,
USA) at 20,000 rpm on ice for 40 s. The homogenates
were centrifuged at 15,000 rpm (JA 25.50 rotor;
Beckman Coulter) for 15 min, the supernatant was
discarded, and the pellets were then stored at 80 C
until they were used. On the day of the experiment, the
pellets were thawed on ice, re-suspended in 15 mL of
Tris buﬀer and centrifuged at 15,000 rpm for 15 min.
The supernatant was discarded, and the pellets
obtained were re-suspended in 35 mL of Tris buﬀer. A
last centrifugation was performed at 15,000 rpm for
15 min; the supernatant was discarded, and the pellets
obtained were ﬁnally suspended in 10 mL of ice-cold
50 mM potassium phosphate buﬀer at pH 7.2.
Saturation binding assays using [3H] DAMGO (range:
0.02–16 nM) (MOP ligand; PerkinElmer, Woodbridge,
ON, Canada) were performed in duplicate on aliquots of
membrane homogenate using a membrane concen-
tration of 2 mg protein/mL. Protein concentrations were
determined by the Lowry method (Lowry et al., 1951)
using reagents from Bio-Rad (Bio-Rad Laboratories,
Mississauga, ON, Canada). The saturation binding
experiments were performed in potassium phosphate
buﬀer, in 5-mL polypropylene tubes (ﬁnal volume of
500 lL). Non-speciﬁc binding was determined in the
presence of 1 lM DAMGO. The tubes were incubated
for 90 min at 25 C. The incubation was terminated by
ﬁltration using ice-cold potassium phosphate buﬀer
(3  2 mL) on a Whatman GF/C ﬁlter (GE Healthcare
Life Sciences, Piscataway, NJ, USA). The ﬁlters were
then placed in vials containing scintillation cocktail. The
radioactivity present on the disks was determined by
liquid scintillation counting using a Beckman Coulter LS-
6500 scintillation counter (Beckman Coulter Canada,
Inc., Mississauga, ON, Canada). The counts per minute
(cpm) were converted into disintegrations per minute
(dpm) using the external standard method, and ﬁnally,
the Bmax was converted into fmol/mg, whereas the Kd
was expressed in nM.
Immunoﬂuorescence
Immunoﬂuorescence was performed to visualize the
expression of MOP in spinal cord of cnr1WT, cnr1KO,
cnr2WT and cnr2KO mice. First, naive mice were brieﬂy
anesthetized with 5% isoﬂurane and perfusion-ﬁxed with
ice-cold 4% paraformaldehyde (PFA; Polysciences, Inc.,
Warrington, PA, USA) in 0.2 M phosphate buﬀer (PB,
pH 7.4) at 4 C (500 mL). The spinal cord was then
isolated by laminectomy, post-ﬁxed in ice-cold 4% PFA
for 2 h and cryoprotected in 30% sucrose in 0.2 M PB
for 48 h. The lumbar segment L4–L6 was then snap-
frozen in 50 C isopentane and stored at 80 C until
sectioning. Afterward, transverse sections were cut on a
microtome (Leica SM2000R; Toronto, Ontario, Canada)
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saline (PBS). The ﬂoating sections were then incubated in
1% sodium borohydride in PBS for 30 min, rinsed twice
with PBS, and incubated for 30 min at room temperature
in a blocking solution containing 3% normal goat serum
(NGS) and 0.3% Triton X-100 in PBS. The sections
were then incubated overnight at 4 C with the guinea
pig anti-MOP primary antibody (cat# GP10106;
Neuromics, Minneapolis, MN, USA) diluted 1:1000 in
the blocking solution. The ﬂoating sections were then
washed in PBS and incubated with a goat anti-guinea
pig secondary antibody conjugated with Alexa Fluor 488
(Molecular Probes, Invitrogen, Carlsbad, CA, USA) at a
concentration of 1:1000 in PBS for 2 h at room
temperature.
Images were collected using an epiﬂuorescence
microscope (Leica DM4000B; Leica Microsystems,
Toronto, Ontario, Canada) to visualize MOP expression
in laminae I–II of the dorsal horn of the mouse spinal
cord (n= 3 animals per genotype). The pictures were
taken with a 5 objective.
[35S]GTPcS binding assay
[35S]GTPcS binding assays using mouse spinal cords
were performed to determine the potency (EC50) and
the eﬃcacy (Emax) of spinal MOP binding sites for each
of the genotypes. First, naive mice were brieﬂy
anesthetized with isoﬂurane 5% and euthanized. The
spinal cords were then rapidly collected and pooled
(n= 4–6 spinal cords per assay) in tubes containing
3 mL of ice-cold buﬀer (50 mM HEPES, 100 mM NaCl,
5 mM MgCl2, 1 mM EDTA and protease inhibitors, pH
7.4) until homogenization. The freshly isolated mouse
spinal cords were then homogenized using a Wheaton
Potter–Elvehjem tissue grinder combined with a Teﬂon
pestle inserted in a Wheaton electric overhead stirrer
(Fischer Scientiﬁc) at approximately 600 rpm on ice, 3
times 5–6 passages. The homogenates were
centrifuged at 13,000 rpm (JA 25.15 rotor; Beckman
Coulter) for 20 min, the supernatant was discarded, and
the pellets were then stored at 80 C until use. On the
day of the experiment, the pellets were thawed on ice,
re-suspended in 3 mL of HEPES buﬀer and centrifuged
at 13,000 rpm for 20 min; subsequently, the supernatant
was discarded, and the pellets obtained were
suspended in 4 mL of ice-cold Tris–HCl buﬀer. Protein
concentrations were determined by the Lowry method
(Lowry et al., 1951) using reagents from Bio-Rad (Bio-
Rad Laboratories, Mississauga, ON, Canada). Aliquots
of spinal cord membrane homogenates were incubated
(20 lg of proteins) in duplicate for 2 h at 30 C in
incubation buﬀer containing 0.1% bovine serum
albumin, 1 mM dithiothreitol (DTT), 10 lM guanosine 50-
diphosphate sodium salt (GDP; Sigma, Oakville, ON,
Canada), 0.1 nM guanosine 50(c-35S-thio) triphosphate
tetralithium salt ([35S]GTPcS, 1250 Ci/mmol, Perkin
Elmer, Montreal, QC, Canada) and protease inhibitors in
the absence or presence of the MOP agonist morphine
(0.01 nM–10 lM), in a total volume of 500 lL. Basal
[35S]GTPcS binding was assessed in the absence of
morphine. Non-speciﬁc binding was measured in thepresence of 10 lM unlabeled GTPcS. The reaction was
terminated by rapid ﬁltration through a Whatman GF/C
ﬁlter (GE Healthcare Life Sciences, Piscataway, NJ,
USA), followed by two washes with 2 mL of ice-cold
assay buﬀer. The ﬁlters were placed in vials containing
scintillation cocktail. Bound radioactivity on the ﬁlters
was determined by liquid scintillation counting using a
Beckman Coulter LS-6500 scintillation counter
(Beckman Coulter Canada, Inc., Mississauga, ON,
Canada). cpm were converted to the percentage of
increase of the agonist-stimulated [35S]GTPcS binding
over the basal binding. The eﬃcacy (Emax) was
determined by the maximum increase in [35S]GTPcS
binding induced by morphine, whereas the potency
(EC50) was obtained from a nonlinear regression
analysis (Prism 5.01).Calculation and statistical analysis
Data are expressed as means ± standard error of the
mean (SEM). Calculations were performed with Excel
2007, and graphs and statistical analysis were performed
using Prism 5.01 (Graph Pad Software, San Diego, CA,
USA). Comparisons of means were performed using
either a two-tailed unpaired t-test, a one-way analysis of
variance (ANOVA) or a two-way ANOVA followed by
Bonferroni’s multiple-comparison test. The binding data
from saturation studies were analyzed using nonlinear
regression to determine Bmax and Kd (Prism 5.01). All
binding data were best ﬁt by a one-site model. The
morphine-stimulated [35S]GTPcS binding data were ﬁt
with a sigmoidal 3-parameter function (Prism 5.01) to
determine the EC50. The comparison of diﬀerences
between basal vs. stimulated [35S]GTPcS binding, as
well as diﬀerences between EC50 within the diﬀerent
genotypes was determined by a one-way ANOVA
followed by Bonferroni’s multiple-comparison test. The
critical level of signiﬁcance was set at 5% (P< 0.05).RESULTS
Intradermal formalin injection induces a similar
biphasic nociceptive proﬁle within all genotypes
In the present study, we observed that for all genotypes,
formalin injection produced a similar biphasic nociceptive
response (acute and inﬂammatory phases) that is typical
of this tonic pain model (Fig. 1). Indeed, nociceptive
responses following i.d. formalin injection were not
diﬀerent within genotypes for both phases of the formalin
test (Fig. 1A; P= 0.8949, Fgenotypes = 0.2738, two-way
ANOVA). These nociceptive eﬀects were also compared
by separate analyses of the acute and inﬂammatory
phases. There were no diﬀerences in the nociceptive
eﬀects of i.d. formalin in the acute phase (Fig. 1B;
A.U.C., F= 2.013, one-way ANOVA) or the inﬂam-
matory phase of the formalin test (Fig. 1C; A.U.C.,
F= 0.1949, one-way ANOVA). These results demon-
strate that all genotypes present a similar nociceptive
proﬁle following i.d. formalin injection into the hind paw in
both phases of the formalin test.
Fig. 1. Nociceptive biphasic proﬁle of intradermal (i.d.) formalin in diﬀerent genotypes. C57BL/6, cnr1WT, cnr1KO, cnr2WT and cnr2KO male mice
were injected with 5.4% intradermal formalin (10 lL) in the plantar surface of the left hind paw, and pain behaviors were recorded for 60 min. (A) In
the early (0–9 min) (highlighted by a gray area) and late phase (21–60 min) of the formalin test, all genotypes present similar biphasic nociceptive
behavioral proﬁles following formalin injection. (B) The A.U.C. analysis indicates that i.d. formalin injection produces a comparative nociceptive
response within all genotypes in the early phase of the formalin test. (C) The A.U.C. analysis of the late phase also reveals that i.d. formalin injection
produces a similar nociceptive proﬁle within all genotypes in the late phase. The numbers in parentheses represent the number of animals per
group. The data are expressed as means ± SEM.
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antinociceptive eﬀects of i.paw morphine in the
formalin test
As expected, local (i.paw) morphine (1 lg) induced an
inhibition of pain behaviors in the C57BL/6 mice (Fig. 2
vs. Fig. 1). Similarly, i.paw morphine reduced formalin-
induced nocifensive behaviors in the cnr1WT mice.However, at the same dose, i.paw morphine had no
analgesic eﬀects in the cnr1KO mice. Thus, compared
to the C57BL/6 and the cnr1WT mice, the pain scores
measured for the cnr1KO mice following i.paw morphine
injection were signiﬁcantly higher in both the acute and
inﬂammatory phases of the formalin test (Fig. 2A;
P< 0.0001, Fgenotypes = 81.37, two-way ANOVA).
Fig. 2. Loss of antinociceptive eﬀects of i.paw morphine in the cnr1KO mice. (A) In the early (highlighted by a gray area) and late phases of the
formalin test, the analgesic eﬀects of i.paw morphine (1 lg/10 lL, 5 min prior to formalin injection) are decreased in cnr1KO mice compared to
cnr1WT mice (⁄P< 0.05, ⁄⁄P< 0.01, ⁄⁄⁄P< 0.001) (two-way ANOVA with Bonferroni’s post hoc test). (B) The A.U.C. analysis of the early phase
reveals a loss of the analgesic eﬀectiveness of i.paw morphine (NP< 0.001 for cnr1KO vs. C57BL/6 mice; £P< 0.05 for cnr1KO vs. cnr1WTmice).
(C) The A.U.C. analysis of the late phase also reveals a loss of the analgesic eﬀectiveness of i.paw morphine (DP< 0.001 for cnr1KO vs. C57BL/6
mice; §P< 0.001 for cnr1KO vs. cnr1WT mice) (one-way ANOVA with Bonferroni’s post hoc test). The horizontal dashed lines (panels B and C)
represent the A.U.C of the C57BL/6 mice, which received NaCl 0.9% for reference purposes (cf. Fig. 1B, C). The numbers in parentheses represent
the number of animals per group. Data are expressed as means ± SEM.
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were also conﬁrmed by separate analyses of the acute
and inﬂammatory phases. We observed a signiﬁcant
increase in the A.U.C. for the acute phase (Fig. 2B;
A.U.C., 7.2 ± 0.9 for cnr1KO vs. 3.1 ± 0.3 for C57BL/6
and 4.5 ± 0.6 for cnr1WT; F= 11.02, one-wayANOVA) and for the inﬂammatory phase (Fig. 2C;
A.U.C., 27.5 ± 3.8 for cnr1KO vs. 7.1 ± 0.8 for C57BL/6
and 9.2 ± 1.6 for cnr1WT; F= 21.54, one-way
ANOVA). These results demonstrate that the i.paw
morphine eﬀectiveness is impeded in the cnr1KO vs.
the cnr1WT mice in both phases of the formalin test.
J. Desroches et al. / Neuroscience 261 (2014) 23–42 29More precisely, under these conditions the analgesic
eﬀects of morphine were completely abolished in the
acute phase and reduced by 87% in the inﬂammatory
phase (Fig. 2B, C). Such a decrease suggests that CB1
receptors are important for the complete expression of
the analgesic eﬀects of i.paw morphine in both phases
of the formalin test.Involvement of CB2 cannabinoid receptors in the
antinociceptive eﬀects of i.paw morphine in the
formalin test
The administration of i.paw morphine (1 lg) induced a
decrease in pain behaviors in C57BL/6 mice (Fig. 3 vs.
Fig. 1) (for comparative purposes, the results presented
for C57BL/6 mice are the same as in Fig. 2). Similarly,
i.paw morphine reduced the formalin-induced pain
behaviors in the cnr2WT mice. However, at the same
dose, i.paw morphine lost its antinociceptive properties
in the cnr2KO mice in the late phase. Indeed, compared
to the C57BL/6 and the cnr2WT mice, the pain score
measured for the cnr2KO mice following i.paw morphine
injection was signiﬁcantly higher only in the
inﬂammatory phase of the formalin test (Fig. 3A;
P< 0.0001, Fgenotypes = 40.42, two-way ANOVA).
There were no diﬀerences in the antinociceptive eﬀects
of i.paw morphine within genotypes when the acute
phase of the formalin test was analyzed (Fig. 3B;
A.U.C., F= 1.29, one-way ANOVA). Conversely, the
loss of antinociceptive eﬀects of i.paw morphine in the
cnr2KO mice over the entire inﬂammatory phase was
conﬁrmed by a signiﬁcant increase in the A.U.C.
compared to the C57BL/6 and the cnr2WT mice
(Fig. 3C; A.U.C., 26.3 ± 3.9 for cnr2KO vs. 7.1 ± 0.8
for C57BL/6 and 11.1 ± 2.8 for cnr2WT; F= 13.23,
one-way ANOVA). Under these conditions, our results
demonstrate a loss of i.paw morphine eﬀectiveness of
76% in the cnr2KO vs. the cnr2WT mice, but only in the
inﬂammatory phase of the formalin test (Fig. 3B, C).
Such a decrease suggests that CB2 receptors are
involved in the analgesic eﬀects of i.paw morphine in
the inﬂammatory phase of the formalin test.Locally mediated antinociceptive eﬀects of i.paw
morphine in the formalin test
To conﬁrm that the previously observed antinociceptive
eﬀects of i.paw morphine were induced by a local eﬀect
of morphine, rather than by a systemic eﬀect, we further
injected morphine contralaterally to the formalin
injection. In the C57BL/6 mice, i.paw morphine (1 lg)
had no analgesic eﬀect when injected in the
contralateral hind paw. Thus, pain scores for
contralateral i.paw morphine were not diﬀerent from pain
scores measured for animals injected with i.paw saline,
but they did diﬀer from pain scores obtained with
ipsilateral i.paw morphine injection in both the acute and
the inﬂammatory phases of the formalin test (Fig. 4A;
P< 0.0001, Ftreatments = 98.36, two-way ANOVA).
These diﬀerences were also observed when the acute
and the inﬂammatory phases were analyzed separately,
as conﬁrmed by the analysis of the acute phase A.U.C.(Fig. 4A, upper inset; A.U.C., 6.7 ± 0.5 for contralateral
i.paw morphine vs. 6.3 ± 0.4 for i.paw saline and
3.1 ± 0.3 for i.paw morphine; F= 25.68, one-way
ANOVA) and the inﬂammatory phase A.U.C. (Fig. 4A,
lower inset; A.U.C., 30.6 ± 1.5 for contralateral i.paw
morphine vs. 28.2 ± 2.0 for i.paw saline and 7.1 ± 0.8
for i.paw morphine; F= 72.09, one-way ANOVA).
In the cnr1WT mice, i.paw morphine (1 lg) had no
analgesic eﬀect when injected into the contralateral hind
paw. Hence, the pain scores for contralateral i.paw
morphine were not diﬀerent from the pain scores
measured for animals injected with i.paw saline, but
they did diﬀer from the pain scores obtained with
ipsilateral i.paw morphine injection in both the acute and
the inﬂammatory phases of the formalin test (Fig. 4B;
P< 0.0001, Ftreatments = 83.51, two-way ANOVA).
These diﬀerences were also observed when the acute
and the inﬂammatory phases were analyzed separately,
as conﬁrmed by the analysis of the acute phase A.U.C.
(Fig. 4B, upper inset; A.U.C., 6.7 ± 0.3 for contralateral
i.paw morphine vs. 7.1 ± 0.5 for i.paw saline and
4.5 ± 0.6 for i.paw morphine; F= 8.60, one-way
ANOVA) and the inﬂammatory phase A.U.C. (Fig. 4B,
lower inset; A.U.C., 31.4 ± 2.6 for contralateral i.paw
morphine vs. 30.2 ± 2.8 for i.paw saline and 9.2 ± 1.6
for i.paw morphine; F= 26.74, one-way ANOVA).
In the cnr2WT mice, i.paw morphine (1 lg) had no
analgesic eﬀect when injected into the contralateral hind
paw. Actually, the pain scores for contralateral i.paw
morphine were not diﬀerent from the pain scores
measured for animals injected with i.paw saline, but
they did diﬀer from the pain scores obtained with
ipsilateral i.paw morphine injection in both the acute and
the inﬂammatory phases of the formalin test (Fig. 4C;
P< 0.0001, Ftreatments = 48.85, two-way ANOVA).
These diﬀerences were also observed when the acute
and the inﬂammatory phases were analyzed, as
conﬁrmed by the analysis of the acute phase A.U.C.
(Fig. 4C, upper inset; A.U.C., 6.3 ± 0.4 for contralateral
i.paw morphine vs. 6.7 ± 0.3 for i.paw saline and
4.3 ± 0.7 for i.paw morphine; F= 7.18, one-way
ANOVA) and the inﬂammatory phase A.U.C. (Fig. 4C,
lower inset; A.U.C., 29.5 ± 1.3 for contralateral i.paw
morphine vs. 31.1 ± 3.6 for i.paw saline and 11.1 ± 2.8
for i.paw morphine; F= 16.50, one-way ANOVA).
These observations reveal that the eﬀects of i.paw
morphine described in Figs. 2 and 3 are due to its local
as opposed to systemic action in the formalin test.
Involvement of CB1 cannabinoid receptors in the
antinociceptive eﬀects of i.t. morphine in the formalin
test
Because the analgesic eﬀects of morphine are also
mediated by receptors located in the spinal cord, we
also studied whether cannabinoid receptors are involved
in the eﬀects of i.t. morphine. We observed that i.t.
morphine (0.1 lg) induced an inhibition of the
nocifensive behaviors in C57BL/6 mice (Fig. 5).
Similarly, i.t. morphine reduced the formalin-induced
behaviors in the cnr1WT mice. However, at the same
dose, i.t. morphine had no analgesic eﬀects in the
Fig. 3. Loss of antinociceptive eﬀects of i.paw morphine in cnr2KO mice. (A) In the late phase of the formalin test, the analgesic eﬀects of i.paw
morphine (1 lg/10 lL, 5 min prior to formalin injection) are decreased in cnr2KO mice compared to cnr2WT mice (⁄⁄⁄P< 0.001) (two-way ANOVA
with Bonferroni’s post hoc test). (B) The A.U.C. analysis reveals that i.paw morphine preserves its analgesic eﬀectiveness in the early phase of the
formalin test. (C) The A.U.C. analysis of the late phase reveals a loss of analgesic eﬀectiveness for i.paw morphine (eP< 0.001 for cnr2KO vs.
C57BL/6 mice (for reference purposes, the results presented for the C57BL/6 mice are the same as in Fig. 2); &P< 0.01 for cnr2KO vs. cnr2WT
mice) (one-way ANOVA with Bonferroni’s post hoc test). The horizontal dashed lines (panels B and C) represent the A.U.C of the C57BL/6 mice,
which received NaCl 0.9% for reference purposes (cf. Fig. 1B, C). The numbers in parentheses represent the number of animals per group. Data are
expressed as means ± SEM.
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cnr1WT mice, the pain score measured for the cnr1KO
mice following i.t. morphine injection was signiﬁcantly
higher both in the acute and the inﬂammatory phases of
the formalin test (Fig. 5A; P< 0.0001,
Fgenotypes = 186.90, two-way ANOVA). Thesediﬀerences observed in the antinociceptive eﬀects were
also conﬁrmed by separate analyses of the acute and
the inﬂammatory phases. We observed a signiﬁcant
increase in the acute phase A.U.C. (Fig. 5B; A.U.C.,
7.5 ± 0.5 for cnr1KO vs. 4.7 ± 0.5 for C57BL/6 and
5.1 ± 0.6 for cnr1WT; F= 8.07, one-way ANOVA) and
Fig. 4. Contralateral i.paw morphine injection did not inhibit formalin-induced pain behavior. (A) In the early and the late phases of the formalin test
in C57BL/6 mice, ipsilateral i.paw morphine (1 lg/10 lL, 5 min prior to formalin injection) produced a decrease in formalin-induced pain behaviors
compared to contralateral i.paw morphine (⁄P< 0.05, ⁄⁄P< 0.01, ⁄⁄⁄P< 0.001) (two-way ANOVA with Bonferroni’s post hoc test) (for analysis
purpose, the results presented for i.paw saline and ipsilateral i.paw morphine were taken from Figs. 1–3). These data show that the antinociceptive
eﬀects of i.paw morphine were local rather than systemic. The A.U.C. analyses of the early and late phases of the formalin test validate the absence
of antinociceptive eﬀects for contralateral i.paw morphine (Phase I; .P< 0.001 vs. ipsilateral i.paw morphine; Phase II; oP< 0.001 vs. ipsilateral
i.paw morphine) (one-way ANOVA with Bonferroni’s post hoc test). (B) In the early and late phases of the formalin test in the cnr1WT mice,
ipsilateral i.paw morphine (1 lg/10 lL, 5 min prior to formalin injection) produced a decrease in the formalin-induced pain behaviors compared to
contralateral i.paw morphine (⁄P< 0.05, ⁄⁄P< 0.01, ⁄⁄⁄P< 0.001) (two-way ANOVA with Bonferroni’s post hoc test). The A.U.C. analyses of the
early and late phases of the formalin test validate the absence of antinociceptive eﬀects for contralateral i.paw morphine (Phase I; hP< 0.05 vs.
ipsilateral i.paw morphine; Phase II; XP< 0.001 vs. ipsilateral i.paw morphine) (one-way ANOVA with Bonferroni’s post hoc test). (C) In the early
and the late phases of the formalin test in the cnr2WT mice, i.paw morphine (1 lg/10 lL, 5 min prior to formalin injection) produced a decrease in
formalin-induced pain behaviors compared to contralateral i.paw morphine (⁄P< 0.05, ⁄⁄P< 0.01, ⁄⁄⁄P< 0.001) (two-way ANOVA with
Bonferroni’s post hoc test). The A.U.C. analyses of the early and late phases of the formalin test validate the absence of antinociceptive eﬀects for
contralateral i.paw morphine (Phase I; RP< 0.05 vs. ipsilateral i.paw morphine; Phase II; bP< 0.001 vs. ipsilateral i.paw morphine) (one-way
ANOVA with Bonferroni’s post hoc test). The numbers in parentheses represent the number of animals per group. Data are expressed as
means ± SEM.
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Fig. 5. Loss of antinociceptive eﬀects of i.t. morphine in cnr1KOmice. (A) In the early and late phases of the formalin test, the analgesic eﬀects of i.t.
morphine (0.1 lg/5 lL, 5 min prior to formalin injection) are decreased in cnr1KO mice compared to cnr1WT mice (⁄P< 0.05, ⁄⁄P< 0.01,
⁄⁄⁄P< 0.001) (two-way ANOVA with Bonferroni’s post hoc test). (B) The A.U.C. analysis of the early phase reveals a loss of the analgesic
eﬀectiveness of i.t. morphine (€P< 0.01 for cnr1KO vs. C57BL/6 mice; P< 0.05 for cnr1KO vs. cnr1WT mice). (C) The A.U.C. analysis of the late
phase also reveals a loss of the analgesic eﬀectiveness of i.t. morphine (¥P< 0.001 for cnr1KO vs. C57BL/6 mice; 1P< 0.001 for cnr1KO vs.
cnr1WTmice) (one-way ANOVA with Bonferroni’s post hoc test). The numbers in parentheses represent the number of animals per group. Data are
expressed as means ± SEM.
32 J. Desroches et al. / Neuroscience 261 (2014) 23–42the inﬂammatory phase (Fig. 5C; A.U.C., 35.5 ± 2.5 for
cnr1KO vs. 7.5 ± 0.9 for C57BL/6 and 9.5 ± 1.6 for
cnr1WT; F= 78.42, one-way ANOVA). These results
demonstrate that i.t. morphine analgesia was greatly
impaired in the cnr1KO mice for both phases of theformalin test. Indeed, at this dose of i.t. morphine, its
analgesic eﬀect was almost completely abolished in
both phases of the formalin test, thus supporting a
major role for CB1 receptors in the analgesic eﬀects of
morphine in this tonic pain context.
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antinociceptive eﬀects of i.t. morphine in the formalin
test
The injection of i.t. morphine (0.1 lg) induced a robust
inhibition of pain behaviors in C57BL/6 mice (Fig. 6)
(for comparative purposes, the results presented for
C57BL/6 mice are the same as in Fig. 5). Similarly, i.t.Fig. 6. Loss of antinociceptive eﬀects of i.t. morphine in cnr2KO mice. (A) In t
(0.1 lg/5 lL, 5 min prior to formalin injection) are decreased in cnr2KO mic
(two-way ANOVA with Bonferroni’s post hoc test). (B) The A.U.C. analysis in
early phase of the formalin test. (C) The A.U.C. analysis of the late phase reve
(#P< 0.001 for cnr2KO vs. C57BL/6 mice (for reference purposes, the result
for cnr2KO vs. cnr2WT mice) (one-way ANOVA with Bonferroni’s post hoc te
group. Data are expressed as means ± SEM.morphine reduced the formalin-induced pain behaviors
in the cnr2WT mice. However, at the same dose, i.t.
morphine had no analgesic eﬀects in the cnr2KO mice
in the late phase. Thus, compared to the C57BL/6
and the cnr2WT mice, the pain score measured for
the cnr2KO mice following i.t. morphine injection was
signiﬁcantly diﬀerent only in the inﬂammatory phase
of the formalin test (Fig. 6A; P< 0.0001,he late phase of the formalin test, the analgesic eﬀects of i.t. morphine
e compared to cnr2WT mice (⁄P< 0.05, ⁄⁄P< 0.01, ⁄⁄⁄P< 0.001)
dicates that i.t. morphine preserves its analgesic eﬀectiveness in the
als a loss of analgesic eﬀectiveness for i.t. morphine in the late phase
s presented for C57BL/6 mice are the same as in Fig. 5); P< 0.001
st). The numbers in parentheses represent the number of animals per
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the antinociceptive eﬀects of i.t. morphine in the cnr2KO
mice over the entire inﬂammatory phase was conﬁrmed
by a signiﬁcant increase in the A.U.C. compared to
C57BL/6 and cnr2WT mice (Fig. 6C; A.U.C., 30.8 ± 2.7
for cnr2KO vs. 7.5 ± 0.9 for C57BL/6 and 11.8 ± 0.9
for cnr2WT; F= 50.72, one-way ANOVA). The eﬀect of
morphine in the acute phase of the formalin test was
similar for all genotypes (Fig. 6B; A.U.C., F= 0.37,
one-way ANOVA). These results therefore revealed a
90% loss of i.t. morphine eﬀectiveness in the cnr2KO
vs. the cnr2WT mice speciﬁcally in the inﬂammatory
phase of the formalin test. Such a decrease suggests
that CB2 receptors have an important role in the
analgesic eﬀects of i.t. morphine in the inﬂammatory
phase of the formalin test.Eﬀect of formalin on thickness and edema of the hind
paw
To verify whether the absence of CB1 or CB2 receptors
impacts the development of formalin-induced
inﬂammation, which in turn might aﬀect the analgesic
properties of morphine, we measured the maximal paw
thickness and edema following the injection of formalin
for various treatments and genotypes.
Both the thickness and the edema (volume)
signiﬁcantly increased in the formalin-injected hind paw
vs. the contralateral side 60 min after formalin injection
(data not shown). As shown in Table 1, the maximal
thickness of the formalin-injected hind paw for each
genotype did not diﬀer between treatments (Table 1;
P= 0.9036, Ftreatments = 0.1875 for C57BL/6;
P= 0.7126, Ftreatments = 0.4611 for cnr1WT;
P= 0.1249, Ftreatments = 2.157 for cnr1KO; P= 0.3699,
Ftreatments = 1.106 for cnr2WT; P= 0.1217,
Ftreatments = 2.183 for cnr2KO, one-way ANOVA).
Similarly, the edema induced by formalin did not diﬀer
across treatments within each genotype (Table 1;Table 1. Eﬀects of formalin on paw thickness and edema
Maximal thicknessa (mm)
Saline i.paw Morphine i.pa
C57BL/6 1.96 ± 0.05 1.93 ± 0.08
cnr1WT 1.99 ± 0.02 1.95 ± 0.05
cnr1KO 2.15 ± 0.01 1.95 ± 0.09
cnr2WT 2.04 ± 0.06 2.07 ± 0.05
cnr2KO 2.16 ± 0.12 2.06 ± 0.04
Volumeb (mL/g)%
Saline i.paw Morphine i.pa
C57BL/6 0.88 ± 0.03 0.90 ± 0.03
cnr1WT 0.82 ± 0.04 0.87 ± 0.05
cnr1KO 0.83 ± 0.02 0.85 ± 0.04
cnr2WT 0.88 ± 0.03 0.79 ± 0.04
cnr2KO 0.83 ± 0.02 0.79 ± 0.03
Maximal thickness and edema were evaluated 60 min after formalin injection into the left
Data are expressed as means ± SEM (n= 6 per group).
a Maximal thickness was measured with a digital micrometer and expressed in mm.
b The volume of the inﬂamed hind paw was determined by water displacement using a pl
body weight of the animal (mL/g).P= 0.3631, Ftreatments = 1.124 for C57BL/6;
P= 0.2454, Ftreatments = 1.498 for cnr1WT;
P= 0.1312, Ftreatments = 2.108 for cnr1KO; P= 0.1443,
Ftreatments = 2.015 for cnr2WT; P= 0.0821,
Ftreatments = 2.581 for cnr2KO, one-way ANOVA). These
results demonstrated that treatments did not inﬂuence
the maximal thickness or the edema in the formalin test.
Finally, the maximal thickness and the volume of the
ipsilateral hind paw were analyzed to observe whether
genotype aﬀected the development of inﬂammation. As
shown in Table 1, the maximal thickness of the
formalin-injected hind paw did not diﬀer between
genotypes (Table 1; P= 0.2765, Fgenotypes = 1.359
for saline i.paw; P= 0.3497, Fgenotypes = 1.165 for
morphine i.paw; P= 0.9809, Fgenotypes = 0.1017 for
saline i.t.; P= 0.3068, Fgenotypes = 1.273 for morphine
i.t., one-way ANOVA). Moreover, the edema of the
formalin-injected hind paw also did not diﬀer between
genotypes (Table 1; P= 0.4067, Fgenotypes = 1.039
for saline i.paw; P= 0.1450, Fgenotypes = 1.882 for
morphine i.paw; P= 0.3496, Fgenotypes = 1.166 for
saline i.t.; P= 0.2178, Fgenotypes = 1.552 for morphine
i.t., one-way ANOVA). These results demonstrated that
genotype did not inﬂuence the maximal thickness or the
edema in the formalin test.Cannabinoid receptors are not involved in the
antinociceptive eﬀects of s.c. morphine in the
formalin test
Because a signiﬁcant contribution of the analgesic eﬀects
of morphine is mediated by receptors located in the brain
(periaqueductal gray, rostroventral medulla), we also
evaluated the contribution of CB1 and CB2 receptors
following systemic morphine administration. As
anticipated, s.c. morphine (3 mg/kg) induced an
inhibition of pain behaviors in the C57BL/6 mice, but
only in the late phase of the formalin test (Fig. 7).
Surprisingly, in contrast to what we observed followingw Saline i.t. Morphine i.t.
1.94 ± 0.06 1.90 ± 0.05
1.93 ± 0.08 2.01 ± 0.05
1.91 ± 0.05 1.99 ± 0.03
1.95 ± 0.05 2.00 ± 0.04
1.96 ± 0.03 1.96 ± 0.03
w Saline i.t. Morphine i.t.
0.85 ± 0.02 0.83 ± 0.04
0.81 ± 0.06 0.72 ± 0.03
0.76 ± 0.04 0.76 ± 0.03
0.77 ± 0.04 0.76 ± 0.05
0.73 ± 0.04 0.72 ± 0.03
hind paw.
ethysmometer and expressed as the percentage of paw volume relative to the total
Fig. 7. Antinociceptive eﬀects of s.c. morphine are maintained in the mouse formalin test. All three genotypes (C57BL/6, cnr1KO and cnr2KO)
present similar biphasic nociceptive behavioral proﬁles following morphine 3 mg/kg s.c. injection (10 min prior to formalin injection). (A) In the late
phase of the formalin test, the analgesic eﬀects of s.c. morphine are preserved in cnr1KO and cnr2KO mice. (B) The A.U.C. analysis indicates that
s.c. morphine preserves its analgesic eﬀectiveness in the early phase of the formalin test. (C) The A.U.C. analysis of the late phase also reveals that
s.c. morphine preserves its analgesic properties. The numbers in parentheses represent the number of animals per group. Data are expressed as
means ± SEM.
J. Desroches et al. / Neuroscience 261 (2014) 23–42 35i.paw and i.t. morphine (Figs. 2, 3, 5 and 6), s.c. morphine
signiﬁcantly reduced the formalin-induced nocifensive
behaviors in the inﬂammatory phase in the cnr1KO and
the cnr2KO mice (Fig. 7). Hence, pain behaviors
following the injection of s.c. morphine were not diﬀerent
within genotypes in both phases of the formalin test
(Fig. 7A; P= 0.9622, Fgenotypes = 0.04, two-way
ANOVA). There were no statistically signiﬁcant
diﬀerences in the antinociceptive eﬀects of s.c.morphine when the acute phase of the formalin test was
analyzed (Fig. 7B; A.U.C., F= 0.55, one-way ANOVA)
nor when the inﬂammatory phase of the formalin test
was analyzed (Fig. 7C; A.U.C., F= 0.01, one-way
ANOVA). Notably, s.c. morphine had no antinociceptive
eﬀects in the acute phase: there were no diﬀerences in
the A.U.C. of s.c. morphine 3 mg/kg compared to saline
i.paw (Fig. 7B vs. Fig. 1B; A.U.C., P= 0.1266,
t= 1.667 and df = 10, two-tailed unpaired t-test).
36 J. Desroches et al. / Neuroscience 261 (2014) 23–42Together, our results demonstrate that in contrast to i.paw
and i.t. morphine, s.c. morphine preserved its
antinociceptive properties in the cnr1KO and the
cnr2KO mice in the inﬂammatory phase of the formalin
test and, therefore, suggest that cannabinoid receptors
do not signiﬁcantly contribute to the analgesic eﬀects of
s.c. morphine.Cannabinoid receptors are not involved in the
antinociceptive eﬀects of s.c. morphine in the hot-
water immersion tail-ﬂick test
To test whether cannabinoid receptors are involved in
the antinociceptive eﬀects of s.c. morphine in acute
pain relief, we used the hot-water immersion tail-ﬂick
test (tail immersion test in a water bath at 52 C)
to measure the antinociceptive eﬀects of 1, 3 and
10 mg/kg s.c. morphine. As shown in Fig. 8A–C,
genotype did not produce any signiﬁcant diﬀerence inFig. 8. Antinociceptive eﬀects of s.c. morphine are maintained in the mice
water at 52 C) were recorded every 10 min (from 0 to 60 min) following th
cnr1KO, cnr2WT and cnr2KO male mice. (A–C) Morphine at 1, 3 and 10
diﬀerence between genotypes. (D) The %MPE of s.c. morphine at 20 min (pe
were no signiﬁcant diﬀerences between genotypes compared to C57BL/6 fo
eﬀects of morphine (one-way ANOVA with Bonferroni’s post hoc test). The
Data are expressed as means ± SEM.the baseline latency to tail withdrawal compared to
C57BL/6 mice (P= 0.1904, Fgenotypes = 1.572, two-
way ANOVA). In all genotypes, s.c. morphine produced
a time- and dose-dependent analgesia that peaked at
20 min post-injection (P< 0.0001, Ftime = 64.57 for
1 mg/kg s.c. morphine; P< 0.0001, Ftime = 163.7
for 3 mg/kg s.c. morphine; P< 0.0001, Ftime = 583.2
for 10 mg/kg s.c. morphine, two-way ANOVA). Latency
to tail withdrawal returned to baseline by 40 to 60 min
after the s.c. morphine injection. The %MPE values of s.c.
morphine were calculated from the latencies to tail
withdrawal that were obtained 20 min post-injection
(Fig. 8D). At any dose, the analgesic eﬀect of s.c.
morphine did not diﬀer between genotypes; %MPE1mg/
kg (16.0 ± 2.3% for C57BL/6, 18.3 ± 1.1% for cnr1WT,
12.3 ± 2.5% for cnr1KO, 19.9 ± 2.4% for cnr2WT and
18.3 ± 1.0% for cnr2KO; F= 2.26), %MPE3mg/kg
(37.7 ± 2.6% for C57BL/6, 37.5 ± 2.3% for cnr1WT,
33.6 ± 1.8% for cnr1KO, 40.1 ± 2.5% for cnr2WT andtail-ﬂick test. Tail-ﬂick latencies (s) to noxious heat (tail immersion in
e s.c. injection of morphine 1, 3 and 10 mg/kg in C57BL/6, cnr1WT,
mg/kg produced signiﬁcant time-dependent antinociception with no
ak antinociceptive eﬀects) was calculated for each dose tested. There
r each dose tested; thus, genotype did not modify the antinociceptive
numbers in parentheses represent the number of animals per group.
Fig. 9. Deletion of the CB1 or CB2 receptors has no eﬀect on the expression of MOP in the spinal cord. Immunoﬂuorescence of spinal MOP
revealed that the expression of MOP in laminae I and II of the dorsal horn of the spinal cord did not diﬀer between cnr1WT (A) and cnr1KO (B) mice
or between cnr2WT (C) and cnr2KO mice (D).




cnr1WT 44.50 ± 2.34 1.75 ± 0.27
J. Desroches et al. / Neuroscience 261 (2014) 23–42 3739.9 ± 2.2% for cnr2KO; F= 1.30) and %MPE10mg/kg
(93.7 ± 2.9% for C57BL/6, 86.7 ± 1.2% for cnr1WT,
91.2 ± 3.0% for cnr1KO, 95.0 ± 2.2% for cnr2WT and
87.8 ± 3.6% for cnr2KO; F= 1.80, one-way ANOVA).cnr1KO 43.43 ± 5.99 2.32 ± 0.86
cnr2WT 34.32 ± 5.82 2.21 ± 1.03
cnr2KO 33.23 ± 4.74 4.70 ± 1.50
[3H]DAMGO saturation binding assays were performed in mouse spinal cord
preparations.
Data are expressed as means ± SEM (n= 3 per group).
a Bmax represents the amount of MOP binding sites in spinal cord of mice
expressed as fmol/mg of protein.
b Kd represents the aﬃnity of [
3H]DAMGO for MOP in the spinal cord extracts
and is expressed in nM.No diﬀerences were detected in spinal MOP
expression between the wild-type and the knockout
mice using immunoﬂuorescence
In an eﬀort to determine whether the inactivation of CB1 or
CB2 receptors aﬀects the expression pattern of MOP, we
ﬁrst compared the MOP-like immunoﬂuorescence
staining in spinal cords of the cnr1WT (Fig. 9A), cnr1KO
(Fig. 9B), cnr2WT (Fig. 9C), and cnr2KO mice (Fig. 9D).
Although qualitative (at best), the immunoﬂuorescence
labeling revealed similar expression patterns of MOP in
laminae I and II of the dorsal horn of the spinal cord in
all genotypes.No diﬀerences were detected in spinal MOP
expression and binding properties between wild-type
and knockout mice using saturation binding assays
To verify if the loss of the antinociceptive eﬀects of
morphine in the cnr1KO and the cnr2KO mice could be
the consequence of a lower level of MOP expression or
of altered binding capacities, we performed saturation
binding assays in spinal cord membrane extracts from
these mice. As shown in Table 2, [3H]-DAMGO
saturation binding assays revealed that the level ofspinal MOP (Bmax) did not signiﬁcantly diﬀer between
the cnr1WT and the cnr1KO mice (P= 0.8759,
t= 0.1664 and df = 4) or between the cnr2WT and the
cnr2KO mice (P= 0.8916, t= 0.1452 and df = 4). We
further found that the aﬃnity (Kd) of DAMGO for spinal
MOP remained unchanged between the cnr1WT and
the cnr1KO mice (P= 0.5616, t= 0.6322 and df = 4)
and between the cnr2WT and the cnr2KO mice
(P= 0.2424, t= 1.370 and df = 4, two-tailed unpaired
t-test). Thus, diﬀerences observed in i.paw and i.t.
morphine analgesic eﬀectiveness are apparently not
caused by decreases in the levels of expression or
reduced binding aﬃnity of MOP in cnr1KO and cnr2KO
mice, at least at the level of the spinal cord.





over basal binding; %)
C57BL/6 87.50 ± 26.80 29.73 ± 2.93
cnr1WT 121.20 ± 38.25 31.86 ± 1.09
cnr1KO 105.50 ± 26.93 38.01 ± 3.82
cnr2WT 127.60 ± 43.76 37.99 ± 6.97
cnr2KO 93.81 ± 15.82 46.83 ± 5.58
[35S]GTPcS binding assays were performed in mouse spinal cord membrane
preparations.
Data are expressed as means ± SEM (n= 3 per group).
a The potency (EC50) of morphine was determined as the concentration (nM)
required to reach 50% of the maximal possible eﬀect (i.e., 50% of the maximal
[35S]GTPcS binding).
b The eﬃcacy (Emax) represents the maximum functional response induced by
morphine, i.e., maximal [35S]GTPcS binding, and is expressed as the percentage
increase over basal binding (%).
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between wild-type and knockout mice using
[35S]GTPcS binding assay on mice spinal cord
To assess if the inactivation of CB1 or CB2 receptors
might alter the G protein coupling of MOP in the spinal
cords of transgenic mice, we performed [35S]GTPcS
binding assays using spinal cord extracts. As shown in
Table 3, the stimulation of [35S]GTPcS binding by
morphine was used as a functional measure of the
status of G protein coupling to the receptor. We found
that morphine increased the binding of [35S]GTPcS in
spinal cord extracts with similar potency (EC50) and
eﬃcacy (Emax) in the C57BL/6 compared to the cnr1WT
and the cnr1KO mice (P= 0.7558, Fpotency = 0.2935
and P= 0.1841, Feﬃcacy = 2.273, one-way ANOVA)
and to the cnr2WT and the cnr2KO mice (P= 0.6386,
Fpotency = 0.4837 and P= 0.1638, Feﬃcacy = 2.483,
one-way ANOVA). Thus, diﬀerences observed in the
i.paw and the i.t. morphine analgesic eﬀectiveness are
apparently not caused by a decrease in the functional
activity of spinal MOP within the diﬀerent genotypes, as
the ability of morphine to activate G protein is not
modiﬁed. Along with previous results, these data
provide direct evidence of apparently normal functional
activity of spinal MOP in wild-type and knockout mice.
DISCUSSION
In the present study, we demonstrated that the
inactivation of either CB1 or CB2 receptors in mice
impairs the analgesic eﬀects of i.paw and i.t. morphine
when assessed with the formalin test. By contrast, the
analgesic eﬀectiveness of s.c. morphine was preserved
in these transgenic mice, both in the formalin test and in
the hot water immersion tail-ﬂick test. We found that the
loss of analgesic eﬀectiveness of morphine was neither
the consequence of impaired expression and binding
properties of MOP, nor of its G protein coupling
eﬃciency. Although we have not identiﬁed the exact
mechanisms by which cannabinoid receptors inﬂuence
morphine-induced analgesia, our ﬁndings further support
the existence of a functional interaction between thecannabinoid and opioid systems, at least in the
periphery and in the spinal cord.
It is now well recognized that the endocannabinoid
and opioid systems share similar distributions in several
brain areas as well as in the spinal cord and in the
peripheral sites of pain processing (Di Marzo, 2008;
Bodnar, 2012). Even if the molecular and cellular
mechanisms involved in this process are not clearly
established, cannabinoids and opioids are known to
produce analgesic synergy in various animal models of
pain (Welch, 2009; Parolaro et al., 2010). Indeed,
previous studies using selective cannabinoid receptor
antagonists have suggested that CB1 receptors are
involved in peripheral (da Fonseca Pacheco et al.,
2008) and central morphine antinociception (Pacheco
Dda et al., 2009) and that CB2 receptors are partially
involved in these eﬀects (da Fonseca Pacheco et al.,
2008). By contrast, the antinociceptive eﬀects of
systemic morphine remained unaﬀected by CB1
receptor ablation in response to both chemical (Miller
et al., 2011) and thermal noxious stimuli (Ledent et al.,
1999; Valverde et al., 2000; Miller et al., 2011). In fact,
the roles of CB1 receptors described by pharmacological
studies performed in wild-type mice were often not
conﬁrmed by studies using cnr1KO mice (Miller et al.,
2011; Raﬀa and Ward, 2012). Notably, most studies
using pharmacological tools have employed the high-
aﬃnity CB1 antagonist/inverse agonist AM251 to
investigate potential interactions between MOP and CB1
receptors (Trang et al., 2007; da Fonseca Pacheco
et al., 2008; Haghparast et al., 2009; Pacheco Dda
et al., 2009). However, AM251 was recently found to
display direct antagonist properties with respect to MOP
(Seely et al., 2012). Therefore, some of the reported
eﬀects of this antagonist on MOP functions may not be
mediated by the CB1 receptors but rather by a direct
action on MOP (Seely et al., 2012), which might explain
the discrepancies between pharmacological and genetic
approaches (Miller et al., 2011).
To better characterize the roles of the CB1 and CB2
receptors in modulating the opioid system, we studied
the impact of disrupting these receptors on morphine-
induced analgesia in mice. While our experiments,
performed in knockout animals, exclude potential
confounding eﬀects of cannabinoid receptor antagonists,
one could still argue that genetically modiﬁed mice may
develop unidentiﬁed adaptations that could mask the
role of cannabinoid receptors (Miller et al., 2011).
However, it was shown that disruption of CB1 receptors
did not alter the mRNA levels of MOP in mouse dorsal
root ganglia and spinal cord (Hojo et al., 2008). By
contrast, cnr1KO mice were shown to have increased
brain levels of substance P, enkephalin, and dynorphin
(Zimmer et al., 1999). Regarding opioids, this
observation might indicate a role for CB1 in the tonic
regulation of these peptides rather than a consequence
of developmental adaptation. Although there is still no
information regarding putative developmental changes
in response to CB2 receptor inactivation, there is no
reason to believe that the loss of morphine analgesia
observed in our study is the result of compensatory
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Indeed, in our experiments, the mice were found to
behave normally, to be equally sensitive to i.d. formalin
and to tail immersion in hot water, and to develop
similar levels of formalin-induced edema and
inﬂammation.
Aside from adaptation, direct receptor–receptor
interaction and interaction between intracellular
pathways are other putative mechanisms able to
impede morphine-induced analgesia in cnr1KO and
cnr2KO mice. Indeed, MOP and CB1 receptors were
shown to physically interact when co-expressed in the
same cells (Rios et al., 2006). Physical interaction
between the MOP and the CB1 receptors was also
evidenced by another group that used
electrophysiological approaches to demonstrate the
existence of a functional heterodimer (Hojo et al., 2008).
In vivo, heterodimer formation requires that both
receptors co-localize in the same neuron. Hence, it has
been demonstrated that MOP and CB1 receptors co-
localize in dendritic spines in the caudate putamen,
periaqueductal gray, dorsal horn of the spinal cord and
presynaptic terminals (Hohmann et al., 1999; Rodriguez
et al., 2001; Salio et al., 2001; Pickel et al., 2004;
Vigano et al., 2005; Wilson-Poe et al., 2012). Another
study has recently described functional interactions
between forebrain MOP and CB2 receptors and the
impact of this interaction on agonist-mediated signaling
(Paldyova et al., 2008). There is growing evidence that
heterodimerization can generate receptors with novel
pharmacological properties (Jordan and Devi, 1999;
Bouvier, 2001; Devi, 2001). Indeed, the attenuation of
CB1 receptor-mediated signaling following MOP
activation (Rios et al., 2006) or a decrease in the
functions of MOP induced by the constitutive activity of
CB1 receptors (Canals and Milligan, 2008) have been
shown. A recent study demonstrated that there is a
decrease in DOP activity associated to its interaction
with CB1 receptors (Bushlin et al., 2012), therefore
suggesting that cannabinoid receptors may have
important impacts on opioid receptor functions. In the
present study, we have demonstrated that there were
no signiﬁcant diﬀerences in the pattern of spinal MOP
expression nor in its binding properties in wild-type mice
compared to cnr1KO and cnr2KO mice. Moreover, we
found that both the eﬃcacy and the potency of spinal
MOP’s G protein coupling remained unaﬀected by CB1
or CB2 inactivation. It is therefore unlikely that the loss
of morphine analgesia in cnr1KO and cnr2KO mice is
the consequence of spinal MOP malfunction or
downregulation due to the absence of MOP’s
heterodimerization with either CB1 or CB2 receptors.
Admittedly however, our experimental design cannot
exclude the possibility that cannabinoid receptors
interfered with intracellular pathways of MOP,
downstream of G proteins.
One could argue that the loss of morphine analgesia
in cnr1KO and cnr2KO mice can be the consequence of
a direct eﬀect of morphine on cannabinoid receptors.
However, the analgesic eﬀects of morphine were often
shown to be completely abolished in MOP KO animalsdemonstrating that the eﬀects of morphine is mainly
mediated by this receptor, at least in vivo (Matthes
et al., 1996; Sora et al., 2001; Mizoguchi et al., 2003).
Another mechanism that may explain our observations
is the possibility that transgenic mice have a disrupted
basal endocannabinoid tone that impairs the ability of
i.paw and i.t. morphine to produce antinociception.
Endocannabinoids were in fact shown to be involved in
the regulation of antinociception following i.paw (da
Fonseca Pacheco et al., 2008) and
intracerebroventricular (i.c.v.) (Pacheco Dda et al.,
2009) injections of morphine. Indeed, although brain
levels of endocannabinoids remained unchanged after
the acute administration of morphine, chronic treatment
with morphine produced a widespread decrease in brain
2-arachidonoylglycerol (2-AG) without signiﬁcantly
changing anandamide levels (Vigano et al., 2003). In
support of a role of endocannabinoids in i.paw and i.t.
morphine-induced analgesia, we observed diﬀerent
consequences of CB1 and CB2 receptors invalidation in
the antinociceptive eﬀects of morphine on the two
phases of the formalin test. While we found that
morphine analgesia was attenuated in both phases of
the formalin test in the cnr1KO mice, the cnr2KO mice
only showed diﬀerent eﬀects of morphine-induced
analgesia in the inﬂammatory phase. A possible
interpretation of these results is that following i.paw and
i.t. morphine administration, anandamide (high-aﬃnity
CB1 agonist/low-aﬃnity CB2 agonist) may be rapidly
released to primarily act at CB1 receptors, thus
participating in the attenuation of the early stages of
nociception of the formalin test. In cnr1KO mice, the
analgesic eﬀect of anandamide on the ﬁrst phase of the
formalin test would be absent while it would remain
unchanged in cnr2KO mice (due to the presence of
CB1). By contrast, the release of the non-selective
endogenous 2-AG may produce a more sustained
modulatory eﬀect on inﬂammatory pain via both CB1
and CB2 receptors.
At ﬁrst glance, it might appear puzzling that s.c.
morphine-induced analgesia remained unaﬀected in both
the formalin test and the tail-ﬂick test. Indeed, previous
studies have demonstrated that morphine analgesic
eﬃcacy requires activity at both spinal and supraspinal
sites (Siuciak and Advokat, 1989; Miaskowski et al.,
1993; Rossi et al., 1993; Kolesnikov et al., 1996).
Analgesic synergy between MOP and CB1 receptor
agonists, ibuprofen, and paracetamol (the latter
modulate cannabinoid synthesis) was also shown to play
an important role in morphine analgesia (Fletcher et al.,
1997; Kolesnikov et al., 2003; Tham et al., 2005;
Kolesnikov and Soritsa, 2008; Mitchell et al., 2010).
Based on these studies, it would have been logical to
observe an attenuation of the analgesic eﬃcacy of
systemic morphine due to a lack/reduction of a spinal
contribution. However, we found that the analgesic
potency of s.c. morphine was preserved in both the
formalin and the hot water immersion tail-ﬂick tests. Our
observations rather suggest that systemic morphine
principally act via a neuronal network independent of
cannabinoid receptors which therefore remain unaﬀected
40 J. Desroches et al. / Neuroscience 261 (2014) 23–42in cnr1KO and cnr2KO mice. Consequently, the
participation of spinal MOP in the analgesic eﬀects of
systemic morphine would be minimal since i.t. morphine
analgesia is impaired in the same genotypes. In support
to this hypothesis, a series of studies have shown that
systemic morphine produces antinociception principally
via the activation of descending inhibitory projections
releasing serotonin in the dorsal horn of the spinal cord
(Kuraishi et al., 1983; Giordano and Barr, 1988; Dogrul
and Seyrek, 2006; Dogrul et al., 2009). The latter studies
in fact revealed that blockade of spinal serotonin
receptors or pharmacological depletion of serotonin in
the spinal cord attenuates the analgesic eﬀects of
systemic and intracranial morphine (Kuraishi et al., 1983;
Giordano and Barr, 1988; Dogrul and Seyrek, 2006;
Dogrul et al., 2009) as well as other opioid receptor
agonists such as tramadol (Yanarates et al., 2010).
CONCLUSION
We have demonstrated that peripheral and spinal
antinociceptive eﬀects of morphine were decreased in
the inﬂammatory phase of the formalin test in cnr1KO
and cnr2KO mice, whereas its systemic eﬀects were
preserved. These observations further support the
existence of interactions between the cannabinoid and
opioid systems. The loss of peripheral and spinal
morphine analgesia is apparently caused neither by a
decrease in MOP spinal expression nor by altered
binding properties or G protein coupling of this receptor
in cnr1KO and cnr2KO mice. The mechanisms
underlying the loss of morphine analgesia are not clear
but could include the release of endogenous
cannabinoids in structures along the pain pathway or a
disrupted endocannabinoid tone.
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